Form 4: Cyclo Therapeutics Director Toig Receives Stock Grant in Lieu of Cash Compensation

Randall M. Toig, a director of Cyclo Therapeutics, Inc., acquired 33,311 shares of common stock as compensation in lieu of cash.

Summary

• Randall M. Toig, a director at Cyclo Therapeutics, Inc., acquired 33,311 shares of common stock on February 27, 2025.
• The shares were granted as compensation in lieu of cash under the company's non-employee director compensation policy.
• This grant covers director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025.
• The number of shares was calculated based on a closing price of $0.77 per share on February 26, 2025.
• Following the transaction, Toig directly owns 179,137 shares of Cyclo Therapeutics.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reflects a routine transaction of director compensation. The use of stock instead of cash could be seen as slightly positive for the company's financial position.

Positives

• Director compensation is being managed through stock grants, potentially conserving cash for the company.

Industry Context

Director compensation through stock grants is a common practice in publicly traded companies, aligning director interests with shareholder value and potentially conserving company cash.

Comparison to Industry Standards

• Stock grants are a typical component of director compensation packages in similar biotech companies.
• The specific amount and vesting schedule would need to be compared to peer companies to assess if it is within industry norms.
• Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize stock options and grants as part of their director compensation.

Stakeholder Impact

• Shareholders may view the stock grant as a positive sign of aligning director interests with company performance.
• The company conserves cash by issuing stock instead of cash compensation.

Key Dates